Semiquantitative chest computed tomography scoring system to estimate severity in pediatric community-acquired pneumonia

半定量胸部CT评分系统用于评估儿童社区获得性肺炎的严重程度

阅读:1

Abstract

INTRODUCTION: A retrospective study assessed the utility of semiquantitative chest Computed tomography (CT) in diagnosing and determining the severity of community acquired pneumonia (CAP) in children. METHODS: The study included pediatric patients with CAP from January 2019 to December 2023. A semiquantitative chest CT scoring system was used based on the extent of lung inflammatory lesions and hydrothorax. The inter-rater reliability between two observers was assessed. The score was then correlated with laboratory results, identified pathogens, and patient prognosis. Receiver operating characteristic (ROC) analysis was employed to evaluate the diagnostic accuracy of the score for identifying severe cases. RESULTS: The study included 426 patients, with 186 severe cases (43.66%). The intragroup correlation coefficient (ICC) value of the two observers was 0.957 (95% Cl: 0.944-0.970). The results showed a positive correlation between chest CT scores and neutrophil percentage, neutrophil count, and C-reactive protein, procalcitonin, lactate dehydrogenase, and fibrinogen levels and a negative correlation between lymphocyte count and hemoglobin and albumin levels (P < 0.001). The patients with coinfection had higher scores than those with single infections (P < 0.05). There was a positive relationship between the score and fever duration and length of stay (P < 0.001). The area under the curve (AUC) of chest CT score for diagnosing severe cases was 0.805. A score cutoff of >3 had 64.52% sensitivity and 84.17% specificity. CONCLUSION: It is practicable and effective that a semiquantitative chest CT scoring system be used for estimating condition and evaluating prognosis of pediatric CAP.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。